FIGURE 3.
Proposed mechanisms of action of omalizumab. Omalizumab decreases free IgE levels and reduces FcεRI receptor expression on mast cells and basophils. This results in decreased mast cell activation and sensitivity, leading to a reduction in eosinophil influx and activation. Anti-IgE treatment with omalizumab might result in decreased mast cell survival. Omalizumab also reduces dendritic cell FcεRI receptor expression. Reprinted from reference 29, with permission.